We received the visit of Mr. Lars Ploug Hansen, International Director of Pharmacosmos A/S, licensor to our laboratory of Monofer, their exclusive injectable iron isomaltoside.
Laboratorios Richmond, a leading pharmaceutical company and one of the main suppliers of oncological and HIV drugs in Argentina, received more than 1,800 orders for an amount greater than $ 658 MILLION, and will start trading on the Buenos Aires Stock Exchange. The transaction was led by Puente as an organizer and placement agent, together BST (Services and Transactions Bank) that acted as co-placer.
En el marco del 43° Congreso Argentino de Cardiología se presenta el documento conjunto de la Sociedad Argentina de Cardiología (SAC) y de la Federación Argentina de Cardiología (FAC) acerca del rol de la polipíldora (Trinomia) como estrategia de prevención cardiovascular en nuestro país.
As part of the process of constant growth, Laboratorios RICHMOND has inaugurated its new administrative offices in three floors of the building located in Bouchard 680, in downtown Buenos Aires. Thus, it brings together in a single headquarters the Direction, Administration and Finance, Commercialization, International Business, Supplying, Legal Affairs and Human Resources.
Después de casi dos años de trabajo, se presentaron los primeros resultados del Estudio Andes. Se dieron a conocer prometedores avances argentinos en la lucha contra el VIH en un trabajo de la Fundación Huésped con el apoyo de los Ministerios de Ciencia y Tecnología, Salud y de Laboratorios Richmond.
Laboratorios Richmond has announced the launch of TRIVENZ®, the first generic in Argentina with the combination of Efavirenz, Emtricitabine and Tenofovir DF. This product for HIV treatment required the exclusive development of a monolithic tablet to ensure physic-chemical compatibility and bioavailability of the active ingredients.
Reaffirming the commitment to the environment and the community, Laboratorios Richmond obtained its ISO 14001 certification, consolidating its environmental management system under the highest international quality standards.
With the objective of contributing to the professional growth of young people and helping them to integrate into the working world successfully, Laboratorios Richmond adhered to the program that the Municipality of Pilar carries out with students, teachers and authorities of the Technical Schools.
The new TB antimicrobial, developed by researchers and fellows of CONICET together with Laboratorios Richmond, obtained last February the Patent in the US and now received another of the European Patent Office (EPO).
